Pharmacokinetic drug interactions between apigenin, rutin and paclitaxel mediated by P-glycoprotein in rats. Eur J Drug Metab Pharmacokinet. 2015;40(3):267-76.Kumar, K.K., Priyanka, L., Gnananath, K., Babu, P.R., Sujatha, S., 2015. Pharmacokinetic drug interactions between apigenin, ...
Pharmacokinetic Interactions with Rifampicin The antituberculosis drug rifampicin (rifampin) induces a number of drug-metabolising enzymes, having the greatest effects on the expression of cytochrome ... Mikko,Niemi,Janne,... - 《Clinical Pharmacokinetics》 被引量: 756发表: 2003年 Pharmacokinetic Drug...
These drugs are indicated in a variety of infections and are often combined with other drug therapies, thus creating the potential for pharmacokinetic interactions. Macrolides can both inhibit drug metabolism in the liver by complex formation and inactivation of microsomal drug oxidising enzymes and ...
Pharmacokinetic drug inter- actions with theophylline. Clin Pharmacokinet 1984;9: 309-34.Jonkman JH, Upton RA. Pharmacokinetic drug interactions with theophylline. Clin Pharmacokinet. 1984;9:309-34.Jonkman JHG,Upton RA.Pharmacokinetic drug interactions with theophylline.Clinical Pharmacokinetics. 1984...
Interactions may be pharmacodynamic in which interaction is close to the target organ and involves direct antagonism or addition of pharmacological properties. Alternatively interaction may be pharmacokinetic in which one drug, or dietary supplement, alters the absorption, distribution, metabolism or ...
Pharmacokinetic herb-drug interactions (part 1): origins, mechanisms, and the impact of botanical dietary supplements. Phytochemicals have been components of man's diet for millennia and are believed to have played a significant role in steering the functional development o......
As new classes of antimicrobial drugs have become available, and new uses found for older drugs, pharmacokinetic drug interactions with antimicrobials have become more common. Macrolides, fluoroquinolones, rifamycins, azoles and other agents can interact adversely with commonly used drugs, usually by alt...
When polypharmacotherapy is used, there is a potential risk of drug interactions (DIs) [1]. A clinically relevant DI occurs when the efficacy or safety of a drug is altered by the concomitant administration of another medication. In a few cases DIs may prove beneficial, resulting in an incre...
Y Chen,J Mao,CECA Hop - 《Drug Metabolism & Disposition》 被引量: 59发表: 2014年 Physiology-based pharmacokinetic modeling: ready to be used Physiologically-based pharmacokinetic (PBPK) modeling and simulation of the absorption process and drug-drug interactions has been studied for several decades...
Therefore, evaluating the drug–drug interaction (DDI) potential associated with MMAE is important in the clinical development of ADCs. The objective of this work was to build a physiologically based pharmacokinetic (PBPK) model to assess MMAE–drug interactions for vc-MMAE ADCs. Methods A PBPK ...